Century Therapeutics, Inc. (NASDAQ:IPSC – Free Report) – HC Wainwright upped their Q3 2024 EPS estimates for Century Therapeutics in a report issued on Thursday, August 15th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($0.41) per share for the quarter, up from their previous forecast of ($0.52). HC Wainwright currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.94) per share. HC Wainwright also issued estimates for Century Therapeutics’ Q4 2024 earnings at ($0.47) EPS, FY2024 earnings at ($1.71) EPS, Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.50) EPS, Q4 2025 earnings at ($0.52) EPS and FY2025 earnings at ($1.93) EPS.
Century Therapeutics (NASDAQ:IPSC – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.12. Century Therapeutics had a negative return on equity of 59.74% and a negative net margin of 9,742.41%. The business had revenue of $0.77 million during the quarter, compared to analysts’ expectations of $0.55 million.
Get Our Latest Stock Report on IPSC
Century Therapeutics Stock Performance
NASDAQ IPSC opened at $1.71 on Monday. Century Therapeutics has a fifty-two week low of $1.28 and a fifty-two week high of $5.51. The stock has a 50 day simple moving average of $2.41 and a two-hundred day simple moving average of $3.28. The stock has a market cap of $144.50 million, a P/E ratio of -0.77 and a beta of 1.39.
Hedge Funds Weigh In On Century Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in IPSC. Federated Hermes Inc. lifted its position in Century Therapeutics by 0.4% during the fourth quarter. Federated Hermes Inc. now owns 618,482 shares of the company’s stock valued at $2,053,000 after buying an additional 2,500 shares during the period. Avidity Partners Management LP boosted its stake in Century Therapeutics by 23.4% during the fourth quarter. Avidity Partners Management LP now owns 1,355,000 shares of the company’s stock worth $4,499,000 after acquiring an additional 256,500 shares in the last quarter. Abel Hall LLC bought a new stake in Century Therapeutics during the fourth quarter worth about $33,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Century Therapeutics during the first quarter worth about $47,000. Finally, Vanguard Group Inc. grew its stake in shares of Century Therapeutics by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 1,138,653 shares of the company’s stock worth $4,760,000 after buying an additional 14,000 shares during the last quarter. Hedge funds and other institutional investors own 50.20% of the company’s stock.
About Century Therapeutics
Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.
Featured Stories
- Five stocks we like better than Century Therapeutics
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- Using the MarketBeat Dividend Yield Calculator
- 2 Option Strategies to Maximize Profits in a Bear Market
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.